The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.12975 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Yasemin Korkmaz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk University, Konya, Turkey. Hauptthemen laut MEDLINE: Exenatide, Benzhydryl Compounds, Quercetin, Rats, Wistar. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Selcuk University Scientific Research Projects.
Abstract (Originalsprache)
Background
Type 2 diabetes, a metabolic disease that involves extended treatment, is rapidly increasing in humans and animals worldwide.
Objectives
This study aimed to compare monotherapy and combined therapy of exenatide, empagliflozin, and quercetin in 67 Wistar Albino male rats.
Methods
The animals were divided into the following seven groups: healthy control, diabetes control, diabetes + sham, diabetes + exenatide (10 μg/kg), diabetes + empagliflozin (50 mg/kg), diabetes + quercetin (50 mg/kg), and diabetes + combination treatment. The treatments were continued for 8 weeks.
Results
At the end of the experiment, glucose and HbA1c levels decreased with all monotherapy treatments and the combination treatments, while insulin levels increased with exenatide and combined treatments. Adiponectin levels increased with empagliflozin, quercetin, and combined treatments, while leptin levels decreased only with combined treatments. All monotherapies caused an increase in total antioxidant levels. Exenatide and quercetin treatments reduced low‐density lipoprotein (LDL) levels; therewithal, exenatide and combined treatments increased high‐density lipoprotein (HDL) levels. Triglyceride levels decreased in all treatment groups. The homeostatic model assessment for insulin resistance (HOMA‐IR) level decreased with the combined treatment; on the contrary, the homeostatic model assessment for β‐cell activity (HOMA‐β) level increased with empagliflozin, exenatide, and combined treatments.
Conclusion
In conclusion, the antidiabetic effects of exenatide were more pronounced than empagliflozin and quercetin, however, the combined treatment had better antidiabetic and antihyperlipidemic effects than monotherapies. Quercetin could be a supportive or food supplement antidiabetic agent. The exenatide treatment can be recommended for monotherapy in type 2 patients, and the combination of empagliflozin, exenatide, and quercetin may be effective in diabetic patients who need combined therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Selcuk University, Konya, Turkey.
ORCID-Profile: Yasemin Korkmaz, Burak Dik
Förderung
- Selcuk University Scientific Research Projects
Zitieren
APA
Korkmaz, Y., & Dik, B. (2024). The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12975
Vancouver
Korkmaz Y, Dik B. The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12975
BibTeX
@article{Korkmaz2024,
author = {Korkmaz, Yasemin and Dik, Burak},
title = {The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.12975}
}
EUVIMED